Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. - Wikidata - wikimedia - TriplyDB

Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.

Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.

http://www.wikidata.org/entity/Q37373292

about

Diagnosis and management of neuropathies associated with plasma cell dyscrasias.Disease burden of systemic light-chain amyloidosis: a systematic literature review.Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.

P2860

Q34555067-848EB23D-0E56-4F52-9150-B7683C93ABD1 Q38917828-F65291FD-B7B4-43C5-ACCD-B7B5BDE926B1 Q39159810-00F12A88-6DF0-4DF7-B0EA-5AE7F73C5925 Q44060632-808E6742-76EC-4786-9C0C-D707D555E688

P2860

Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.

http://www.wikidata.org/entity/Q37373292

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Modified high-dose melphalan a ...... analysis of SWOG trial S0115.

@en

Modified high-dose melphalan a ...... analysis of SWOG trial S0115.

@nl

type

label

Modified high-dose melphalan a ...... analysis of SWOG trial S0115.

@en

Modified high-dose melphalan a ...... analysis of SWOG trial S0115.

@nl

prefLabel

Modified high-dose melphalan a ...... analysis of SWOG trial S0115.

@en

Modified high-dose melphalan a ...... analysis of SWOG trial S0115.

@nl

P1433

Q37373292-820923A3-FEC1-4829-A427-EC615E8FBFAE

P1476

Q37373292-B91A19D2-966B-4C10-88ED-F9E0F63A6D9B

P2093

Q37373292-1B3747BD-1639-43AC-9732-75706B088DAE

Q37373292-5A633FB9-2479-4A89-818D-9E5558D8D024

Q37373292-6EA94DE1-31FC-460C-8EEF-6A2C0310A166

Q37373292-6FA68B82-A970-45BB-8CE2-AEC45672166F

Q37373292-70585D28-51A5-4852-B760-03FC536D911F

Q37373292-A6D890F4-1C2A-4C85-8F8B-BB1A56F2766D

Q37373292-A9DC1532-B204-4817-99A0-931E358D0D08

Q37373292-BE3A66FC-1995-460E-9342-977BFA8AE2A6

Q37373292-C5D015D7-80F0-4142-9BF6-B4065FF41002

Q37373292-CB3577D9-4222-4B9A-90F5-BC27423499F2

P2860

Q37373292-067E0F8F-DBB2-4DE5-9A81-09BB6AC8118D

Q37373292-0F217C88-FE5C-4766-AEDB-FA8C23B7B873

Q37373292-1FDFC8FE-3992-4C48-8CF8-2AAE303B6354

Q37373292-24366146-698F-4AFB-A875-01D8AB313784

Q37373292-3E0516A0-A991-43AC-8217-6CBB0A83E8F9

Q37373292-4BCAB181-DEA3-4B43-904E-CDE64B36E6FE

Q37373292-5A1CBFE9-FFC4-40DB-9D80-53C59E13EF6F

Q37373292-5C751FC0-D48B-4D34-8D1B-63962D2364EB

Q37373292-6D235178-E5A7-4702-B5A6-EC988647B6AE

Q37373292-7DBA3C03-48E2-4F35-AF94-3E02E95CB0F5

P2888

Q37373292-375F935E-181A-40C0-822A-CF245830B28D

P304

Q37373292-B1A147DD-773D-427A-9BC1-072470F9026E

P31

Q37373292-D56F2A4B-6C6E-486D-A156-0B3212E31A81

P356

Q37373292-099E902D-0C4F-4B20-9FE2-FCA825D38153

P407

Q37373292-C8BFC11E-CB3C-44EC-93DD-CC8BE32933D9

P433

Q37373292-6E45D3AB-D441-4AB5-94E2-9AFF29D151EF

P478

Q37373292-9BBF156B-8E88-4473-9127-6385188108BD

P577

Q37373292-833E04E5-81EB-4838-8109-9BF61E1934E5

P5875

Q37373292-F9BB37B9-13D0-4671-8654-86F08FBEDE9E

P698

Q37373292-470FF014-8A18-485F-A495-4E525AEC68A1

P932

Q37373292-C9081CD3-F5A6-416A-8547-8A358595F574

P356

P1433

Bone Marrow Transplantation

P1476

Modified high-dose melphalan a ...... analysis of SWOG trial S0115.

@en

P2093

A Hoering

http://www.w3.org/2001/XMLSchema#string

B Barlogie

http://www.w3.org/2001/XMLSchema#string

B Mattar

http://www.w3.org/2001/XMLSchema#string

D C Seldin

http://www.w3.org/2001/XMLSchema#string

H F Safah

http://www.w3.org/2001/XMLSchema#string

K T Finn

http://www.w3.org/2001/XMLSchema#string

L A Holmberg

http://www.w3.org/2001/XMLSchema#string

R M Dean

http://www.w3.org/2001/XMLSchema#string

R Sexton

http://www.w3.org/2001/XMLSchema#string

R Z Orlowski

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Lenalidomide after stem-cell transplantation for multiple myeloma

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Molecular mechanisms of amyloidosis.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.

P2888

P304

1537-1542

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2013.98

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

249320599

http://www.w3.org/2001/XMLSchema#string

P698

23852321

http://www.w3.org/2001/XMLSchema#string

P932

3855173

http://www.w3.org/2001/XMLSchema#string